Literature DB >> 23968358

Optical imaging of treatment-related tumor cell death using a heat shock protein-90 alkylator.

Danielle Park1, Bang-Wen Xie, Ermond R Van Beek, Vicky Blankevoort, Ivo Que, Clemens W G M Löwik, Philip J Hogg.   

Abstract

The ability to assess in near-real time the tumor cell killing efficacy of chemotherapy regimens would improve patient treatment and survival. An ineffective regimen could be abandoned early in favor of a more effective treatment. We sought to noninvasively image treatment-related tumor cell death in mice using an optically labeled synthetic heat shock protein-90 (Hsp90) alkylator, 4-(N-(S-glutathionylacetyl)amino)phenylarsonous acid (GSAO). The Hsp90 chaperone is an important element in oncogene addiction and tumor cell survival, and its expression is enhanced by chemotherapy. These factors were predicted to favor the detection of tumor cell death using GSAO. GSAO specifically labeled apoptotic and necrotic tumor cells in culture and cells of comparable morphology in subcutaneous human pancreatic carcinoma tumors in mice. A near-infrared fluorescent conjugate of GSAO was used to noninvasively image cyclophosphamide-induced tumor cell death in murine orthotopic human mammary tumors. The GSAO conjugate did not accumulate in healthy organs or tissues in the mouse, and unbound compound was excreted rapidly via the kidneys. There was a significant increase in the GSAO fluorescence signal in the treated tumors measured either in vivo or ex vivo, and the fluorescence signal colocalized with apoptotic cells in sectioned tumors. The favorable biodistribution of optically labeled GSAO, the nature of its tumor cell target, and its capacity to noninvasively detect tumor cell death should facilitate the application of this compound in studies of the efficacy of existing and new chemotherapeutics.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23968358     DOI: 10.1021/mp4003464

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  6 in total

1.  Necrotic platelets provide a procoagulant surface during thrombosis.

Authors:  Vu Minh Hua; Latasha Abeynaike; Elias Glaros; Heather Campbell; Leonardo Pasalic; Philip J Hogg; Vivien M Y Chen
Journal:  Blood       Date:  2015-10-16       Impact factor: 22.113

2.  Noninvasive molecular imaging of cell death in myocardial infarction using 111In-GSAO.

Authors:  Nobuhiro Tahara; H Reinier Zandbergen; Hans J de Haas; Artiom Petrov; Raghu Pandurangi; Takayoshi Yamaki; Jun Zhou; Tsutomu Imaizumi; Riemer H J A Slart; Mary Dyszlewski; Tiziano Scarabelli; Annapoorna Kini; Chris Reutelingsperger; Navneet Narula; Valentin Fuster; Jagat Narula
Journal:  Sci Rep       Date:  2014-10-29       Impact factor: 4.379

3.  Updated developments on molecular imaging and therapeutic strategies directed against necrosis.

Authors:  Dongjian Zhang; Meng Gao; Qiaomei Jin; Yicheng Ni; Jian Zhang
Journal:  Acta Pharm Sin B       Date:  2019-02-13       Impact factor: 11.413

4.  Novel assay demonstrates that coronary artery disease patients have heightened procoagulant platelet response.

Authors:  L Pasalic; E Wing-Lun; J K Lau; H Campbell; G J Pennings; E Lau; D Connor; H P Liang; D Muller; L Kritharides; P J Hogg; V M Chen
Journal:  J Thromb Haemost       Date:  2018-05-08       Impact factor: 5.824

5.  A first-in-human study of [68Ga]Ga-CDI: a positron emitting radiopharmaceutical for imaging tumour cell death.

Authors:  Ivan Ho Shon; Thomas Hennessy; Jennifer Guille; Michael P Gotsbacher; Angelina J Lay; Bruce McBride; Rachel Codd; Philip J Hogg
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-07-02       Impact factor: 10.057

6.  Dual targeting of mitochondrial function and mTOR pathway as a therapeutic strategy for diffuse intrinsic pontine glioma.

Authors:  Maria Tsoli; Jie Liu; Laura Franshaw; Han Shen; Cecilia Cheng; MoonSun Jung; Swapna Joshi; Anahid Ehteda; Aaminah Khan; Angel Montero-Carcabosso; Pierre J Dilda; Philip Hogg; David S Ziegler
Journal:  Oncotarget       Date:  2018-01-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.